Zonisamide Drug Asset Due Diligence Report 2026

This Zonisamide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

111

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Zonisamide can convert its Small molecule drug profile and T-type calcium channel biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zonisamide (query alias: zonisamide)
Modality / target	Small molecule drug; T-type calcium channel; T-type calcium channel blockers
Highest global status	Approved
Originator	Sumitomo Pharma Co., Ltd.
Active developers	Sumitomo Pharma Co., Ltd., Azurity Pharmaceuticals, Inc., Amdipharm Ltd.

The MCP disease footprint includes Lewy Body Disease, Parkinson Disease, Epilepsies, Partial. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06967012	Phase 4	Recruiting	30	Primary Observational Indicators
JPRN-jRCT2071260023	Phase 1	募集中	168	Part A, Part B, Part F Safety Assessment parameters (Adverse Events, Clinical Laboratory Tests, Vital Signs, 12-Lead Electrocardiogram, Neurological Examination, C-SSRS) Part C Pharmacokinetic Assessment Parameters Part D, Part E Pharmacodynamic Assessment Parameters (EEG), Safety Assessment Parameters (Adverse Events, Clinical Laboratory Tests, Vital Signs, 12-Lead Electrocardiogram, Neurological Examination, C-SSRS), Pharmacokinetic Assessment Parameters
CTR20260102	Not Applicable	已完成	48	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pharmaceutical Interventions for Noise-Induced Hearing Loss-Acute Exposure Treatment

Phase 2; n=3; evaluation: not stated. Reported fields: -; -; -

Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial

Phase 4; n=58; evaluation: not stated. Reported fields: -; Treatment Failure = 11 Participants ; -

Analysis of Excessive Daytime Sleepiness Caused by Anti-seizure Medications: A Single Tertiary Center Experience in Japan (P9-9.015)

Not Applicable; n=207; evaluation: Positive. Reported fields: Adverse Event: excessive daytime sleepiness = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. ; Adverse Event: excessive daytime sleepiness = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. ; Adverse Event: excessive daytime sleepiness = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zonisamide addresses Lewy Body Disease, Parkinson Disease, Epilepsies, Partial. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
	Azurity Pharmaceuticals purchases Eton's neurology portfolio products, including ET-105, ET-104, and ET-101, for the treatment of epilepsy, partial seizures, and neurological disorders.	Not disclosed	US$15.0M upfront; US$30.0M milestones; US$45.0M stated total
2019-01-23	Eton partners with Liqmeds to develop and provide ET-104 for the treatment of neurological condition.	Phase 3	US$0.3M upfront; US$2.1M milestones; US$2.5M stated total
2017-06-22	Ewopharma to distribute Eisai's Halaven, Targretin and Zonegran in 11 CEE countries	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition comprising zonisamide”. The milestone feed surfaced a patent-application signal described as “Formulation and evaluation of fast dissolving film of zonisamide”. The milestone feed surfaced a patent-application signal described as “Preparation method of zonisamide tablet”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO